- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Empowering Nonspecialist Providers and Addressing Gaps in Dementia Care: How Tools and Biomarkers Can Help
Panelists discuss how significant knowledge gaps among nonspecialist providers—particularly regarding differential diagnosis, interpretation of cognitive assessments, and awareness of treatment options—are being addressed through targeted educational initiatives, embedded clinical decision support tools, and collaborative care models to enhance understanding of early Alzheimer diagnosis and treatment importance.
EP: 1.Strategies for Enhancing Early Diagnosis and Implementation of Disease-Modifying Therapies in Alzheimer Disease
EP: 2.Advancing Early Alzheimer Diagnosis: Best Practices for Timely Screening and Detection
EP: 3.Care Pathways for Nonspecialist Providers When Evaluating Patients With Potential Mild Cognitive Impairment
EP: 4.Empowering Nonspecialist Providers and Addressing Gaps in Dementia Care: How Tools and Biomarkers Can Help
EP: 5.Factors to Evaluate When Selecting a Combination of Screening Assessments and Tests for Detecting Alzheimer Disease
EP: 6.From Time Constraints to Reimbursement: Addressing Key Hurdles in Cognitive Screening for Alzheimer Disease
EP: 7.Expanding Access to Alzheimer Disease Care: Leveraging Referral Networks and Telemedicine for Patients in Underserved Areas
EP: 8.Amyloid-Targeting Therapies in Alzheimer Disease: Mechanisms of Action, Efficacy, and Safety Considerations
EP: 9.Real-World Implications of Changes in CDR-SB Score in Patients Receiving Amyloid-Targeting Therapy
EP: 10.Patient Selection for Amyloid-Targeting Therapies: Key Characteristics and Considerations
EP: 11.Understanding the Hesitancy to Prescribe Amyloid-Targeting Therapies for Patients With Alzheimer Disease
EP: 12.Navigating the Risk-Benefit Conversation: Discussing Amyloid-Targeting Therapies With Patients and Caregivers
EP: 13.Criteria for Discontinuing Treatment With an Amyloid-Targeting Therapy
EP: 14.Strategies for Clinicians When Developing Protocols for Managing ARIA
EP: 15.Key Barriers in Managing Patients With Mild Cognitive Impairment Using Amyloid-Targeting Therapies
EP: 16.Access to Diagnostic Tests and Coverage for Amyloid-Targeting Therapies: Payer Considerations
EP: 17.Addressing Concerns About the Financial Impact of Amyloid-Targeting Therapies
EP: 18.Final Thoughts Alzheimer Disease Care
Video content above is prompted by the following:
- What are the biggest knowledge gaps you are seeing among nonspecialist providers (for example, PCPs)?
- How have you addressed these knowledge gaps to ensure these providers have a comprehensive understanding of the importance of early diagnosis and treatment?
Managed Care Reflections: A Q&A With A. Mark Fendrick, MD, and Michael E. Chernew, PhD
December 2nd 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The December issue features a conversation with AJMC Co–Editors in Chief A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design and a professor at the University of Michigan in Ann Arbor; and Michael E. Chernew, PhD, the Leonard D. Schaeffer Professor of Health Care Policy and the director of the Healthcare Markets and Regulation Lab at Harvard Medical School in Boston, Massachusetts.
Read More
